Our Take
A clean exit by strategic buyers leaves EQT with pricing power in a deal that values the company 25% below initial expectations.
Why it matters
PE consolidation in nutraceuticals accelerates as US trade policy uncertainty depresses valuations for export-heavy businesses. TA Associates may restart the process if EQT lowballs.
Do this week
Nutraceutical exporters: audit your US customer concentration before Q3 fundraising cycles to avoid similar valuation haircuts.
EQT cleared the field after Temasek consortium withdrew
Swedish private equity firm EQT emerged as the sole bidder for OmniActive Health Technologies after the only competing consortium withdrew from the auction. The Temasek and Novo Holdings joint bid valued the nutraceuticals manufacturer at ₹5,500-5,800 crore ($660-700M), but was rejected in favor of EQT's superior offer.
TA Associates controls 56% of OmniActive after acquiring the stake in 2021, while founder Sanjaya Mariwala retains a significant minority position. The current valuation represents a 25% discount from initial expectations of $1 billion (₹9,500 crore) communicated to bidders.
OmniActive generates ₹886 crore in annual revenue (company-reported, FY25) from specialty botanicals including vision health ingredients and metabolic supplements. The company maintains vertical integration through direct farmer sourcing of marigold and paprika.
US exposure drives conservative pricing
Bidders discounted OmniActive's valuation due to heavy US market exposure amid trade policy uncertainty. CRISIL noted that "near-term revenue growth from the US is expected to be moderate owing to the deferment of new product launches amid heightened uncertainty surrounding trade policies."
The withdrawal of strategic buyers Temasek and Novo Holdings leaves EQT with enhanced negotiating leverage. TA Associates may abandon current talks and restart a fresh sale process later this year if terms prove unacceptable.
The deal reflects broader PE consolidation in nutraceuticals as financial buyers outbid strategic acquirers spooked by regulatory and trade risks.
Export businesses face valuation pressure
Companies with significant US export exposure should expect similar valuation haircuts during fundraising. OmniActive's 25% discount from initial expectations signals how trade uncertainty translates directly to lower exit multiples.
The competitive dynamics favor PE buyers over strategic acquirers in cross-border deals where regulatory risk creates bidding asymmetries. Strategic buyers with US operations face greater compliance exposure, while financial buyers can price risk more aggressively.
TA Associates' willingness to potentially restart the process demonstrates seller optionality when facing single-bidder scenarios, though timing costs accumulate with each failed auction cycle.